

1 **Title:** Splenic Rupture in a COVID-19 Patient – Case Report

2  
3 **Author 1 name:** Anna C. Crowley

4 **Degrees:** BS

5 **Affiliation:** Alabama College of Osteopathic Medicine, Dothan, AL 36303

6  
7 **Author 2 name:** Raul R. Magadia

8 **Degrees:** MD

9 **Affiliation:** Northeast Alabama Regional Medical Center, Infectious Disease

10  
11 **Author 3 name:** Arianna B. Lanpher

12 **Degrees:** BA

13 **Affiliation:** Alabama College of Osteopathic Medicine, Dothan, AL 36303

14  
15 **About the author:** Anna Crowley is currently a 3<sup>rd</sup> year medical student of the Alabama College of  
16 Osteopathic Medicine, Dothan, Alabama, of a 4-year program. She holds a B.S. degree in Chemical  
17 Engineering from Auburn University, and while in her clinical years at ACOM, she has become passionate  
18 about preventative healthcare and furthering patient education. She is the recipient of the Council of  
19 Osteopathic Student Presidents Association Gold Badge Volunteer Award.

20  
21 **Acknowledgment:** None

22 **Financing:** None

23 **Conflict of interest statement by authors:** No conflicts of interest reported by any of the authors.

24 **Compliance with ethical standards:** As the subject of the case report died, informed consent could not  
25 be obtained. His identity has been protected in the manuscript.

26  
27 **Highlights:**

- 28 - Presentation of a unique case of COVID-19 complicated by non-traumatic splenic rupture  
29 - Diagnostic dilemma of conflicting coagulation studies in a COVID-19 patient with chronic renal  
30 failure requiring hemodialysis and valve replacement requiring warfarin therapy, leading to splenic  
31 rupture, a complication that is associated with hypocoagulable state  
32 - Highlights possibility of fatal splenic rupture in COVID-19 patients with comorbid renal disease and  
33 complex coagulation states, reminding clinicians that rapid diagnosis and surgical correction can  
34 be life-saving

35 **Manuscript word count:** 1,180

36 **Abstract word count:** 119

37 **Number of Figures and Tables:** 2 Figures and 1 Table

1 **Authors Contribution Statement:**

| Contributor Role                            | Role Definition  | Authors |   |   |   |   |   |
|---|--|---------|---|---|---|---|---|
|   |  | 1       | 2 | 3 | 4 | 5 | 6 |
| <b>Conceptualization</b>                    | Ideas; formulation or evolution of overarching research goals and aims.  | X       | X | X |   |   |   |
| <b>Data Curation</b>                        | Management activities to annotate (produce metadata), scrub data and maintain research data (including software code, where it is necessary for interpreting the data itself) for initial use and later reuse. | X       |   |   |   |   |   |
| <b>Formal Analysis</b>                      | Application of statistical, mathematical, computational, or other formal techniques to analyze or synthesize study data.   |         |   |   |   |   |   |
| <b>Funding Acquisition</b>                  | Acquisition of the financial support for the project leading to this publication.  |         |   |   |   |   |   |
| <b>Investigation</b>                        | Conducting a research and investigation process, specifically performing the experiments, or data/evidence collection.   | X       |   |   |   |   |   |
| <b>Methodology</b>                          | Development or design of methodology; creation of models   |         |   |   |   |   |   |
| <b>Project Administration</b>               | Management and coordination responsibility for the research activity planning and execution.   | X       |   |   |   |   |   |
| <b>Resources</b>                            | Provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or other analysis tools.   |         |   |   |   |   |   |
| <b>Software</b>                             | Programming, software development; designing computer programs; implementation of the computer code and supporting algorithms; testing of existing code components.  |         |   |   |   |   |   |
| <b>Supervision</b>                          | Oversight and leadership responsibility for the research activity planning and execution, including mentorship external to the core team.  |         | X |   |   |   |   |
| <b>Validation</b>                           | Verification, whether as a part of the activity or separate, of the overall replication/reproducibility of results/experiments and other research outputs.   |         | X |   |   |   |   |
| <b>Visualization</b>                        | Preparation, creation and/or presentation of the published work, specifically visualization/data presentation.   | X       |   | X |   |   |   |
| <b>Writing – Original Draft Preparation</b> | Creation and/or presentation of the published work, specifically writing the initial draft (including substantive translation).  | X       |   |   |   |   |   |
| <b>Writing – Review &amp; Editing</b>       | Preparation, creation and/or presentation of the published work by those from the original research group, specifically critical review, commentary or revision – including pre- or post-publication stages.   |         | X | X |   |   |   |

2

3

**Personal, Professional, and Institutional Social Network accounts:**

4

- **Facebook: Anna Crowley, Alabama College of Osteopathic Medicine**

5

- **Twitter: @AnnaCro20607085, @ACOMEDU**

6

7

**Discussion points:**

8

1. A case of non-traumatic splenic rupture occurred In a COVID-19 patient with chronic renal failure and fluctuating coagulation studies while receiving therapeutic warfarin.

9

2. In high-risk patients with COVID-19, everyday activities which increase intra-abdominal pressure, such as sneezing, coughing, and defecation, can trigger splenic rupture, with fatal results; a high index of suspicion can be life-saving.

10

3. In patients with COVID-19, non-traumatic splenic rupture should be considered as one of the differential diagnosis in patients who present with abdominal pain and early recognition of the same, owing to a high index of suspicion, can be lifesaving.

11

12

13

14

15

16

17

18

19

20

21

**Publisher's Disclosure:** *This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our readers and authors we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.*

1 **ABSTRACT:**

2  
3 **Background:** It is well known that Coronavirus disease 2019 (COVID-19) causes coagulation changes,  
4 requiring frequent monitoring for potential sequelae such as myocardial infarction and stroke. Non-  
5 traumatic splenic rupture is a rare and poorly understood occurrence in the clinical setting. Possible  
6 causes of nontraumatic splenic rupture include neoplasm, infection, inflammatory disease, iatrogenic and  
7 mechanical causes. Furthermore, increased intrasplenic tension, increased abdominal pressure, and  
8 thrombotic vascular occlusion are three possible mechanisms.

9  
10 **The Case:** We report a case of splenic rupture in a COVID-19 patient. Our patient was a 52 year old  
11 black man, presenting with diarrhea and moderate dyspnea, who was found to be COVID-19 positive. He  
12 had a past medical history significant for end-stage renal disease, chronic anemia, and aortic valve  
13 replacement. In an otherwise uneventful, 7-day hospital course, the patient's stay abruptly resulted in a  
14 nontraumatic splenic rupture and demise. In this report, we have evaluated the likelihood of COVID-19  
15 causing splenic rupture in a patient with no prior splenic disease.

16  
17 **Conclusion:** This case highlights the possibility of splenic rupture in otherwise normally recovering  
18 COVID-19 patients, particularly in the presence of comorbid conditions of renal failure and  
19 anticoagulation, with increased abdominal pressure during routine defecation. This information may assist  
20 in furthering the pathophysiology of COVID-19 and its life-threatening complications. In patients with  
21 COVID-19, non-traumatic splenic rupture should be considered as one of the differential diagnosis in  
22 patients who present with abdominal pain and early recognition of the same, owing to a high index of  
23 suspicion, can be lifesaving.

24  
25 **Key Words:** case report, COVID-19, splenic rupture  
26

1 **INTRODUCTION.**

2

3 While Coronavirus disease 2019 (COVID-19) is known to present with significant pulmonary and cardiac  
4 manifestations, other systemic complications and interactions with pre-existing pathology are being  
5 recognized.<sup>1</sup> As the pandemic has evolved, hypercoagulability and microvascular changes are becoming  
6 more prevalent causes of mortality.<sup>2</sup> Here we describe a case of nontraumatic splenic rupture in a  
7 COVID-19 patient being treated with anticoagulants and routine hemodialysis. Atraumatic splenic rupture  
8 is exceedingly rare and a potentially fatal condition. Causes of atraumatic splenic rupture include  
9 neoplasms, infection, iatrogenic, mechanical and inflammatory states.<sup>3</sup> This case illustrates how  
10 interactions with chronic renal disease and anticoagulation use may be important considerations in the  
11 treatment of complicated COVID-19 patients.

Accepted, in-progress

**1 THE CASE.**

2  
3 History of Present Illness: A 52-year-old black male presented to the Emergency Department with a chief  
4 complaint of diarrhea for 1 day followed by moderate dyspnea. At the time of admission, the BUN/Cr ratio  
5 was 44/11.3, and on admission, the SARS-CoV-2 Antigen by IFA (in-house, Sofia) was positive. The  
6 patient was afebrile (36.9 °C), and the oxygen saturation was 100% on room air.

7  
8 Past Medical History: He had a past medical history of hypertension, hepatitis B (2006), end-stage renal  
9 disease (2005), hyperlipidemia, severe anemia (2008), and aortic valve replacement (2019). Current  
10 medications included warfarin (10mg daily, in addition to supplemental 5mg on M/W/F) due to past  
11 mechanical aortic valve replacement. The patient's goal INR was 2.5-3.5. The patient has a history of  
12 hemodialysis noncompliance and often did not attend the recommended treatments. From laboratory data  
13 in 2019, the patient's average BUN/Cr was 34.2/6.5, respectively. Patient denied any recent travel. He did  
14 not have any personal or family history of leukemia, lymphoma, coagulopathies, DVT/PE, auto-immune  
15 pathology, or other neoplasms.

16  
17 Investigations: Laboratory results on admission were significant for pancytopenia, elevated inflammatory  
18 markers, and elevated coagulation studies. From laboratory data in 2019, the patient had a history of  
19 leukopenia, anemia, platelet count of 160.7 ( $10^3/\mu\text{L}$ ), and an average Hgb/Hct of 8.2/25.6 (g/dL/%),  
20 respectively. Physical exam revealed normal lung sounds, no hepatosplenomegaly, or lymphadenopathy.  
21 Prior to this current admission, the patient was evaluated for further renal disease progression in  
22 December 2018. There was no evidence of splenic injury or splenomegaly on the 2018 abdominal CT.  
23 The patient's pancytopenia was evaluated during his stay at the hospital; both nutritional and viral  
24 etiologies, as well as bone marrow failure, were ruled out with appropriate investigations, as shown in  
25 Table 1. Peripheral smear was unremarkable.

26  
27 Hospital Course: On the second day of admission the patient received dialysis, and over the next six days  
28 underwent a total of three hemodialysis treatments coupled with three separate packed RBC transfusions  
29 because of his severe anemia. His chest radiograph remained clear and diarrhea subsided by Day 2. Due  
30 to the belief that the patient's symptoms were due to COVID-19 initially, no abdominal imaging was  
31 performed on admission. On Day 5 the INR increased to 5.13 and remained above therapeutic range  
32 (2.5-3.5) for the remainder of his hospital course. After the patient's increase in coagulation studies, his  
33 regular warfarin treatment regimen (10mg daily, in addition to supplemental 5mg on M/W/F) was  
34 discontinued on day 6.

35  
36 On the eighth inpatient day, when attempting defecation, the patient felt a "pop" and developed tearing  
37 and burning LLQ flank pain at 8:00. This bowel movement was blood-tinged and loose. His abdominal

1 pain progressed throughout the day, and at 16:00, the internist's physical examination revealed a firm  
2 abdomen with no rebound tenderness. CT scan of the abdomen was compatible with acute splenic  
3 hemorrhage. Before emergency splenectomy could be performed, the patient became hypotensive,  
4 developed cardiac arrest at 18:55, and expired at 19:12.

5  
6 The abdominal CT detected a large amount of heterogenous material surrounding the spleen with small  
7 to moderate amount of free fluid around the spleen, compatible with acute splenic hemorrhage as shown  
8 in Figure 1. Due to abrupt onset of acute intra-abdominal hemorrhage, the patient died prior to  
9 splenectomy or other life-saving interventions. No autopsy was performed.

10  
11 Throughout the patient's stay, he received the standard in-house COVID-19 treatment including five days  
12 of Ascorbic acid (50 mL 2000mg/4 mL IV), Thiamine HCl (2mL 200 mg/2 mL IV), and Zinc Sulfate (20 mg  
13 oral QD), along with his continued warfarin anticoagulation as previously prescribed until its  
14 discontinuation on day 6.

15  
Accepted, in-press

**DISCUSSION.**

We believe this case of non-traumatic splenic rupture in a COVID-19 patient was caused by interactions from COVID-19-related coagulation changes. Based on recent data, COVID-19 has been shown to cause both hypercoagulable and hyperfibrinolytic states in patients.<sup>2</sup> Because our patient was on chronic warfarin therapy and reached supratherapeutic levels during hospital days 5-8, we believe the effects of COVID-19 affected our patient's coagulability and possibly led to his hemorrhagic state and splenic rupture.

While the exact etiology of nontraumatic splenic rupture is not fully understood, three possible mechanisms could explain this patient's unfortunate clinical course: increased intrasplenic tension, increased abdominal pressure, and altered coagulation.<sup>4</sup> We believe the supratherapeutic warfarin levels and hyperfibrinolytic state caused by COVID-19 led to our patient's altered coagulation studies. The process of defecation is a known inciting event for splenic rupture due to the rising intrabdominal pressure and stretching of the splenocolic ligament causing rupture of pre-existing subcapsular hematoma. While the patient had no evidence of pre-existing splenic hematoma or splenomegaly, we believe this was the chief inciting event leading to splenic rupture.<sup>5</sup>

It is relevant to eliminate the other causes of nontraumatic splenic rupture. Because our patient did not receive an autopsy following his death, we cannot be certain that our patient didn't have an underlying primary splenic neoplasm (i.e. splenic marginal zone lymphoma) or primary myelofibrosis. However, these etiologies are extraordinarily rare.<sup>6</sup> Our patient did not present with any clinical or laboratory findings suggestive of an underlying hematological malignancy, and there was no hepatosplenomegaly, enlarged lymph nodes, or systemic B symptoms. Mature B or T cell leukemias are unlikely because the patient's lymphocyte count is within normal range. Hairy cell leukemia can be ruled out because peripheral blood smear typically reveals a pancytopenia with monocytopenia. Primary myelofibrosis typically presents with an enlarged spleen and liver with tear drop cells on blood smear, which was not detected in our patient. Epstein Barr Virus and Cytomegalovirus are not suspected due to absence of atypical lymphocytes and leukocytosis.

Even though microvascular changes, coagulation changes, and defecation can be regarded as the principal causes of splenic rupture in this case, the consequences of repetitive hemodialysis from CRD cannot be overlooked. This is a rare reported complication of hemodialysis, and its exact incidence is not known. However, in a previous study of nontraumatic splenic rupture in a hemodialyzed patient, important risk factors included use of anticoagulants during hemodialysis, uremic coagulopathy, susceptibility to infections, and impaired immune function. These risk factors can occur as long-term complications of hemodialysis, but they are also complications of severe coronavirus infection, which paradoxically is

1 associated with coagulation changes.<sup>7</sup> The exact etiology and pathogenesis cannot be confirmed due to  
2 lack of autopsy, but because of the extremely low incidence of splenic rupture due to hemodialysis, and  
3 the absence of known risk factors in our patient (e.g., infectious mononucleosis, hematologic disease,  
4 splenomegaly, neoplasm), we believe COVID-19 infection is a contributing cause of splenic rupture in our  
5 patient.

6  
7 There have been other recently reported cases of nontraumatic splenic rupture in the setting of COVID-  
8 19. Research demonstrates COVID-19 has a direct effect on the body's secondary lymph tissue.  
9 Following these studies, there is further reason to suspect the virus has the potential to have a direct  
10 effect on the spleen by causing "lymphoid follicle attrition and nodular atrophy in addition to microvascular  
11 thrombosis and necrosis," as stated in a case report by Shaukat, I. and the British Infection Association.<sup>8</sup>

12  
13 In monitoring COVID-19 progression, clinicians monitor inflammatory markers, such as C-reactive Protein  
14 (CRP), Lactate dehydrogenase (LDH), ferritin, lymphocytes, etc. As shown in Table 1, several other  
15 laboratory values are now closely monitored to evaluate the coagulation changes related to the COVID-  
16 19 pathogenesis including d-dimer, fibrinogen, prothrombin time, partial thromboplastin time, platelet  
17 count, and other specific quantifications such as calcium.<sup>9</sup> Although the mechanism is still unknown,  
18 elevated coagulation markers support studies documenting many critically ill COVID-19 patients who  
19 suffer from a thrombotic microvascular event.<sup>10</sup> Studies have suggested that in the setting of COVID-19,  
20 symptoms such as abdominal pain may be an indication for abdominal CT scan on admission and  
21 frequent monitoring throughout the patient's disease progression. In a case of splenic rupture in Poursina  
22 Hospital in Rasht, Iran, a COVID-19 patient had vague abdominal symptoms and subsequent signs of  
23 decompensation. Urgent laparotomy was performed, revealed atraumatic splenic rupture, and  
24 splenectomy was performed. Fortunately, the acuity of these physicians' actions were able to save their  
25 patient's life.<sup>11</sup>

26  
27 Due to the multisystem involvement of COVID-19, coagulation studies are becoming increasingly relevant  
28 in that the virus can cause both hypercoagulable and hemorrhagic changes. We are assuming that our  
29 patient's hyperfibrinolytic state led to his splenic hemorrhage. While coronavirus remains a heavily  
30 studied topic both microbiologically and clinically, it is pertinent that clinicians grow more cognizant of  
31 emerging complications related to COVID-19. This case highlights the importance of monitoring  
32 coagulation studies while maintaining a high index of suspicion for rare but life-threatening intra-  
33 abdominal complications. In patients with COVID-19, non-traumatic splenic rupture should be considered  
34 as one of the differential diagnosis in patients who present with abdominal pain and early recognition of  
35 the same, owing to a high index of suspicion, can be lifesaving.



1 **REFERENCES**

- 2 1. Temgoua MN, Endomba FT, Nkeck JR, Kenfack GU, Tochie JN, Essouma M. Coronavirus  
3 Disease 2019 (COVID-19) as a Multi-Systemic Disease and its Impact in Low- and Middle-  
4 Income Countries (LMICs). *SN Compr Clin Med*. 2020;1-11.
- 5 2. Kelsey Gockman, Alyssa Harbaugh, Yogendra Kanthi, Jason S. Knight, Daniel A. Lawrence,  
6 Jacqueline A. Madison, et al. Plasma tissue plasminogen activator and plasminogen activator  
7 inhibitor-1 in hospitalized COVID-19 patients. *Scientific Reports*. 2021 Jan; 11: 1580.
- 8 3. D. Candinas, B. Gloor, A Hostettler, P. Renzulli, A. M. Schoepfer. Systematic Review of  
9 Atraumatic Splenic Rupture. *Br J Surg*. 2009 Oct;96(10):1114-21. doi: 10.1002/bjs.6737.
- 10 4. Ayfer Aktas, Mustafa Aldemir, Ercan Gedik, Sadullah Girgin, Mustafa Aldemir, Celalettin Keles,  
11 Mehmet Cudi Tuncer. Non-Traumatic Splenic Rupture: Report of Seven Cases and Review of the  
12 Literature. *World Journal of Gastroenterology*. 2008 Nov; 14(43): 6711–6716.
- 13 5. Chikashi Gotoh, Kouji Masumoto, Kentara Ono, Toko Shinkai, Yasuhisa Urita. A Rare  
14 Mechanism of Delayed Splenic Rupture Following the Nonoperative Management of Blunt  
15 Splenic Injury in a Child. *Surgical Case Reports*. 2018 Dec; 4: 75.
- 16 6. M. M. Al-Hawary, S. Azar, R. K. Kaza, I.R. Francis. Primary and Secondary Neoplasms of the  
17 Spleen. 2010 Aug; 10(1): 173–182.
- 18 7. Se-Ho Chang, Hyun-Jung Kim, Gyeong-Won Lee, Jong Deog Lee, Dong Jun Park. Spontaneous  
19 Splenic Rupture in a Hemodialysis Patient. *Yonsei Medical Journal, Yonsei University College of*  
20 *Medicine*. 2005 Jun 30; 46(3): 435–438.
- 21 8. Shaukat I, Khan R, Diwakar L, Kemp T, Bodasing N. Atraumatic splenic rupture due to covid-19  
22 infection. *Clinical infection in practice*. 2021 Apr 1;10:100042.
- 23 9. Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Ting Yu, Fei Zhou, et al. Clinical Course and Risk  
24 Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort  
25 Study. *The Lancet*. 2020 Mar; 395(10229):1054-1062.
- 26 10. David Berlin, Joanna Harp, Jeffrey Laurence, Cynthia Magro, J. Justin Mulvey, Steven Salvatore,  
27 et al. Complement Associated Microvascular Injury and Thrombosis in the Pathogenesis of  
28 Severe COVID-19 Infection: A Report of Five Cases. *Translational Research : the Journal of*  
29 *Laboratory and Clinical Medicine*. 2020 Jun; 220: 1–13.
- 30 11. Mobayen, M., Yousefi, S., Mousavi, M., & Anbaran, A. S. (2020). The presentation of  
31 spontaneous splenic rupture in a COVID-19 patient: a case report. *BMC surgery*, 20(1), 1-5.
- 32 12. Judith A. James, Doruk Erkan, Joan T. Merrill, Jerald Winakur. Emerging Evidence of a COVID-  
33 19 Thrombotic Syndrome Has Treatment Implications. *Nature Reviews Rheumatology*. 2020 July;  
34 16: 581-589.

1 **FIGURES AND TABLES.**

2

3 **Figure 1.** Abdominal CT confirming splenic rupture

4

5 **Impression Per Radiology:**


6 1. Large amount fo heterogenous material surrounding the spleen with small to moderate amount of free  
7 fluid in the abdomen compatible with acute splenic hemorrhage.

8 2. Renal findings compatible with autosomal dominant polycystic kidney disease.

9 3. Small bilateral pleural effusions, greater on the left.

10 4. Atherosclerosis.

11



1 **Table 1.** Inpatient laboratory values

|                                   | Ref.<br>Range               | Day 0    | D1       | D2       | D3       | D4       | D5       | D6       | D7       |
|-----------------------------------|-----------------------------|----------|----------|----------|----------|----------|----------|----------|----------|
| WBC<br>(10 <sup>3</sup> /μL)      | 4.5-10.4                    | 1.5      | 1.6      | 1.7      | 1.8      | 2.8      | 3.5      | 5.2      | 5.4      |
| RBC<br>(10 <sup>6</sup> /μL)      | 3.7-5.3                     | 2.41     | 2.37     | 2.11     | 2.29     | 2.10     | 1.64     | 2.04     | 1.91     |
| Hgb<br>(g/dL)/HCT<br>(%)          | 11.0-<br>16.0/35.0-<br>47.0 | 7.8/23.5 | 7.4/22.9 | 6.6/20.8 | 6.9/22.2 | 6.5/20.4 | 5.2/16.5 | 6.5/19.9 | 6.0/18.2 |
| Platelet<br>(10 <sup>3</sup> /μL) | 140-440                     | 54       | 62       | 60       | 59       | 76       | 68       | 72       | 69       |
| INR                               |                             | 2.93     | --       | 2.24     | 2.22     | 2.84     | 5.13     | 4.65     | 4.73     |
| PT (s)                            | 9.8-11.6                    | 29.8     | --       | 23.1     | 22.9     | 28.9     | 50.8     | 46.2     | 47       |
| aPTT (s)                          | 23.1-31.6                   | 56.6     | --       |          |          |          |          |          |          |
| AST (unit/L)                      | 2-33                        | 24       |          |          |          |          |          |          |          |
| ALT (unit/L)                      | 13-61                       | 12       |          |          |          |          |          |          |          |
| Albumin<br>(gm/dL)                | 3.4-5                       | 2.7      |          |          |          |          |          |          |          |
| Ferritin<br>(ng/mL)               | 8.0-252.0                   | 2184.6   | --       |          |          |          |          |          |          |
| CRP (mg/L)                        | 0.0-3.0                     | 24.5     | --       |          |          |          |          |          |          |
| Procalcitonin<br>(ng/mL)          | <0.10                       | 0.52     | --       |          |          |          |          |          |          |
| Sed Rate<br>(mm/h)                | 0-30                        | 53       | --       |          |          |          |          |          |          |
| D-dimer                           | 0.19-0.5                    | 2.92     | --       |          |          |          |          |          |          |
| LDH (unit/L)                      | 87-241                      | 360      | --       |          |          |          |          |          |          |
| BUN/Cr                            | 7-18/0.6-<br>1.3            | 44/11.3  | --       |          |          |          |          |          |          |
| Lymphocyte<br>(%)                 |                             | 25.5     | 43.0     | 36.5     | 32.6     | 27.3     | 25.1     | 22.9     | 16.5     |
| Monocyte<br>(%)                   |                             | 9.4      | 13.3     | 17.1     | 11.4     | 9.1      | 13.6     | 12.9     | 11.9     |

2